PATH
Menu

PATH has developed a low-cost and straightforward approach for protecting aluminum-adjuvanted vaccines from irreversible damage that results from freezing. Many current vaccines of importance to global health contain an aluminum-salt adjuvant (such as aluminum hydroxide or aluminum phosphate) and could benefit from this freeze-protection technology. There is no intellectual property barrier for manufacturers wishing to adopt the technology; it has been placed in the public domain. This technical dossier summarizes the rationale for freeze protection, application of the technology to specific vaccines, the data obtained to date, and comments on the likely regulatory pathway for vaccines incorporating the technology.

Corporate author(s): PATH

Publication date: February 2014

Available materials

English

Freeze-Protection of Aluminum-Adjuvanted Vaccines

648 KB PDF

Hard copies are not available.

Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.

Region: Global

See also:

Vaccines and immunizationMiscellaneous

Health technologiesVaccine delivery

For advocates and policymakersHealth technologies

About PATH's workAdvancing technologies

For more information…

Contact: PATH Publications
Email: publications@path.org
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA